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Abstract
Purpose 123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-
fluoropropyl) nortropane (123I-FP-CIT) dopamine transporter
single photon emission computed tomography (DAT SPECT)
and 123I-metaiodobenzylguanidine (MIBG) myocardial scin-
tigraphy can be used to assist in the diagnosis of patients with
dementia with Lewy bodies (DLB). We compared the diag-
nostic value of these two methods in differentiating DLB from
Alzheimer’s disease (AD). Furthermore, we evaluated wheth-
er a combination of DAT SPECT and MIBG myocardial scin-
tigraphy would provide a more useful means of differentiating
between DLB and AD.
Methods Patients with AD (n=57) and patients with DLB
(n=76) who underwent both DAT SPECT and MIBG myo-
cardial scintigraphy were enrolled. The sensitivity, specificity,
and accuracy of both methods as well as their combination for
differentiating DLB from AD were calculated. Moreover, we
examined whether symptoms of the patients with DLB were
associated with the patterns of the abnormalities displayed on
DAT SPECT and MIBG myocardial scintigraphy.
Results The sensitivity and specificity of differentiating DLB
from AD were 72.4 and 94.4 % by the heart to mediastinum
ratio ofMIBG uptake, 88.2 and 88.9% by the specific binding
ratio on DAT SPECT, and 96.1 and 90.7 % by their combina-
tion, respectively. The combined use of DAT SPECT and
MIBG myocardial scintigraphy enabled more accurate differ-
entiation between DLB and AD compared with either DAT
SPECT or MIBG myocardial scintigraphy alone. There was a
significantly higher frequency of parkinsonism in the abnor-
mal DAT SPECT group than the normal DAT SPECT group.
On the other hand, there was a higher frequency of the appear-
ance of rapid eye movement (REM) sleep behavior disorder in
the abnormal MIBG uptake group than the normal MIBG
uptake group.
Conclusion These results suggested that using a combination
of these scintigraphic methods is a useful and practical ap-
proach to differentiate DLB from AD.
Keywords 123I-FP-CIT . DAT . SPECT .MIBGmyocardial
scintigraphy . Alzheimer’s disease . Dementia with Lewy
bodies
Introduction
Dementia with Lewy bodies (DLB) is recognized as the sec-
ond most common cause of degenerative dementia in older
people, following Alzheimer’s disease (AD). In some cases,
the clinical differentiation of patients with DLB from those
with AD may be difficult because of overlapping clinical
and pathological features. The importance of accurate identi-
fication of patients with DLB lies particularly in its pharma-
cological management, with favorable responsiveness to cho-
linesterase inhibitors but severe sensitivity to the adverse ef-
fects of neuroleptic agents [1].
The first consensus clinical diagnostic criteria for DLB that
were developed [2] had high specificity for the diagnosis of
probable DLB, but poor sensitivity [3]. In view of these difficul-
ties the consensus criteria were revised [4], with the addition of
new features to improve the diagnosis of DLB. Abnormal find-
ings on dopamine transporter (DAT) imaging were considered
the most important among the various neuroimaging features
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listed as one of the suggestive features of DLB, whereas findings
from other neuroimaging techniques, including 123I-
metaiodobenzylguanidine (MIBG) myocardial scintigraphy
were listed only as supportive of DLB (commonly present in
DLB but not proven to have diagnostic specificity).
123I-2β-Carbomethoxy-3β-(4-iodophenyl)-N-(3-
fluoropropyl) nortropane (123I-FP-CIT), a ligand that binds to
the presynaptic DAT, can be used to analyze the integrity of the
nigrostriatal projection pathway. 123I-FP-CITDATsingle photon
emission computed tomography (SPECT) has been used in a
large number of trials to identify the in vivo loss of DATs in
the striatum of patients with presynaptic parkinsonism [5, 6].
Previous studies showed that DAT SPECT substantially en-
hanced the accuracy of the diagnosis of DLB compared with
clinical criteria alone and has a high diagnostic accuracy in dif-
ferentiating DLB patients from non-DLB patients [7–16].
On the other hand, recent studies have indicated that MIBG
myocardial scintigraphy is able to detect early disturbances of
the sympathetic nervous system in DLB, independently of the
duration of disease and autonomic failure, and provides diagnos-
tic information useful for differentiating DLB fromAD [17–24].
The usefulness of both DAT SPECTandMIBGmyocardial
scintigraphy for the diagnosis of DLB has recently been sug-
gested by two meta-analysis studies [25, 26]. Moreover, the
utility of the combination of DAT SPECTand MIBG myocar-
dial scintigraphy was reported in patients with DLB and
Parkinson syndrome (PS) [14, 15, 27–29]. Furthermore, the
use of 123I-FP-CITwas approved by the Japanese Ministry of
Health, Labour and Welfare in February 2014.
In the present study, we performed both DAT SPECT and
MIBGmyocardial scintigraphy in patients with DLB and AD,
and compared the diagnostic value of these two methods in
differentiating DLB from AD. We also examined whether a
combination of DAT SPECT and MIBG myocardial scintig-
raphy would provide a more useful means of differentiating
between DLB and AD compared with either of the two
methods alone. Moreover, we examined whether the particu-
lar symptoms of the DLB patients would be associated with
the abnormalities observed on DAT SPECT and MIBG myo-
cardial scintigraphy. To our knowledge, this is the first study
to evaluate the diagnostic value of a combination of these two
methods in differentiating DLB from AD.
Materials and methods
Patients
A total of 133 outpatients with AD or DLB from the Memory
Disorder Clinic at the Department of Geriatric Medicine, Tokyo
MedicalUniversity,were enrolled in this study fromMarch 2014
until September 2014. They had a dementia severity of 1 (mild)
or 2 (moderate) based on the Clinical Dementia Rating [30] and
Mini-Mental State Examination (MMSE) [31] scores between
14 and 26. All subjects underwent both DAT SPECTandMIBG
myocardial scintigraphy. The interval between undergoing the
two methods of imaging was less than 2 months. Of the 133
patients, 57 had a diagnosis of probable AD based on the Na-
tional Institute of Neurological and Communicative Disorders
and Stroke and Alzheimer’s Disease and Related Disorders As-
sociation (NINCDS-ADRDA) criteria [32] and the other 76 had
a diagnosis of probable (36 patients) and possible DLB (40
patients) based on the consortium on DLB international work-
shop criteria [4], except for lowDATuptake in the basal ganglia,
which was also included because one of the aims of this study
was to determine whether DAT SPECT is useful for the diagno-
sis of DLB.
All patients underwent general physical, neurological, and
psychiatric examinations, extensive laboratory tests, and com-
puted tomography (CT) or magnetic resonance imaging
(MRI) to establish a clinical diagnosis and to exclude other
potential causes of dementia. None of the subjects had any
history of cerebrovascular disease, other degenerative dis-
eases, infarction in the region of the basal ganglia or intracra-
nial lesions on brain MRI, thyroid disease, diabetes mellitus,
or previous relevant cardiac disease, nor were taking any med-
ications known to interact with the striatal binding of 123I-FP-
CIT (e.g., cocaine, amphetamines, bupropion, selective sero-
tonin reuptake inhibitors, etc.) [33, 34] or that affect MIBG
accumulation [35].
The Hachinski ischemic score [36] was less than 4 in all
patients. Based on the UK Parkinson’s Disease Society Brain
Bank criteria [37], parkinsonism was defined as the presence
of bradykinesia, associated with one or more of the following
three features: tremor, rigidity, or postural instability.
None of the patients with probable AD had fluctuating
cognition, visual hallucinations, parkinsonism, or rapid eye
movement (REM) sleep behavior disorder (RBD) as deter-
mined by three geriatric neurologists (H.H., T.U., and S.S.).
This study was approved by the Ethics Committee of To-
kyo Medical University. Informed consent was obtained from
all subjects (either the patients themselves or their closest rel-
ative) before entry, following a detailed explanation of the
study’s aim. In accordance with the research plan, the fees of
MIBGmyocardial scintigraphy and DAT SPECTexamination
for the patients with ADwere paid for using the research funds
of our department. All procedures were in accordance with the
ethical standards on human investigation and with the princi-
ples of the Declaration of Helsinki.
Image analysis
123I-MIBG myocardial scintigraphy
After the patient had rested for 15 min in the supine position,
111 MBq of 123I-MIBG was injected intravenously. Early and
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delayed SPECT were performed at 20 min and 4 h after the
injection, respectively. Planar imaging for 5 min in the anterior
projection was performed during SPECT automatically. Pla-
nar scan and SPECTwere performed with a dual-head gamma
camera equipped with a low-energy, high-resolution parallel-
hole collimator (PRISM 2000VP, Picker). After the scatter
correction, relative organ uptake was determined by setting
the region of interest (ROI) on the anterior view [38]. The
heart to mediastinum (H/M) ratio was calculated by dividing
the count density of the left ventricular ROI by that of the
mediastinal ROI, according to the standard method described
previously [17, 39]. The normal H/M ratios in the early phase
and the delayed phase as well as the washout ratios obtained
from eight normal elderly controls in our institute (three men
and five women, mean age 76.5±5.8 years) were 2.56±0.37,
2.53±0.38, and 32.90±10.26, respectively. Values were con-
sidered abnormal if they were less than 2 SDs below the con-
trol mean. For the comparison study, H/M ratios calculated
from the ROI counts obtained by delayed SPECT were used
for analysis, because delayed scans display the neuronal up-
take of MIBG more explicitly [17].
DAT SPECT imaging and specific binding ratio analysis
Three hours after injection of approximately 185MBq of 123I-
FP-CIT, projection data were obtained in a 128×128 matrix
on a Siemens Symbia T16 mounted with low- to medium-
energy general purpose (LMEGP) collimators. Projection data
were acquired for 28 min. Data were reconstructed by ordered
subset expectationmaximization (OSEM)method (iteration 8,
subset 6) using Flash 3D software (Siemens) and corrected for
attenuation by CT. The specific binding ratio (SBR) was semi-
quantitatively calculated using DAT VIEW software (Nihon
Medi-Physics, Tokyo, Japan) based on Bolt’s method, as de-
scribed in detail elsewhere [40]. For this study, we used SBR
as the mean value of the right and left SBRs. The control
group for DAT SPECT consisted of 18 subjects without any
present or previous neurological disease (7 men and 11 wom-
en, mean age 78.6±6.5 years). The mean SBR of the controls
was 5.84±0.83. Values were considered abnormal if they were
less than 2 SDs below the control mean.
Statistical analysis
Values were expressed as means±SD and analyzed by
Student’s t test, χ2 test, and one-way analysis of vari-
ance. A p value of less than 0.05 was considered to
indicate a statistically significant difference between the
two groups. The sensitivity and specificity of the respec-
tive diagnostic index (H/M ratios of MIBG uptake in the
delayed phase, SBR on DAT SPECT, and combined DAT
SPECT and MIBG myocardial scintigraphy) for the dif-
ferentiation between DLB and AD were assessed using
receiver-operating characteristic (ROC) analysis. For the
combined use of DAT SPECT and MIBG myocardial
scintigraphy, we developed the combined DAT*MIBG
index, defined as (SBR*H/M in the delayed phase).
The cutoff values (mean−2 SD) were 1.82, 1.77, 12.38,
and 4.18 for the H/M in the early phase, the H/M in the
delayed phase, washout ratio, and SBR, respectively. We
adopted the best value in ROC analysis as the cutoff
value (10.18) of the DAT*MIBG index. All data were
statistically analyzed using MedCalc software (version
13.3.0.0, MedCalc Software, Mariakerke, Belgium).
Results
Table 1 shows the characteristics of the patients. No signifi-
cant differences in the two groups were found in terms of age,
length of education, duration of disease, and MMSE scores.
The number of women was significantly higher in the AD
group (p<0.01).
Mean H/M ratios of MIBG uptake in the early phase
(3.2±0.5 vs 2.2±0.8, p<0.0001, cutoff 1.82) and delayed
phase (2.9±0.6 vs 1.7±0.8, cutoff 1.77, p<0.0001,
Fig. 1, left) were significantly lower and mean washout
ratios (21.7±10.0 vs 38.3±10.2, cutoff 12.38, p<0.0001)
were significantly higher in patients with DLB than in
patients with AD. ROC analysis demonstrated that there
was no significant difference in diagnostic accuracy
among these three ratios. The area under the curve was
0.864 for the delayed phase, 0.859 for the washout ratio,
and 0.835 for the early phase.
Mean SBRs on DAT SPECT were markedly lower in pa-
tients with DLB than in those with AD (5.2±1.0 vs 2.7±1.3,
cutoff 4.18, p<0.0001, Fig. 1, middle). Mean values of the
DAT*MIBG index (described in the “Materials and methods”
section) were significantly lower in patients with DLB than in
those with AD (15.3±4.5 vs 4.6±3.0, cutoff 10.18, p<0.0001,
Fig. 1, right). The sensitivity and specificity in differentiating
DLB from AD were 72.4 and 94.4 % by the H/M ratio of
MIBG uptake in the delayed phase, 88.2 and 88.9 % by the
Table 1 Characteristics of the patients
AD (n=57) DLB (n=76)
Age (years) 81.4±6.1 80.2±4.9
Sex (male/female) 10/47* 42/34
Length of education (years) 10.3±3.2 11.8±2.8
Duration of disease (years) 2.8±1.2 3.2±0.9
MMSE score 22.5±5.4 22.4±4.8
MMSEMini-Mental State Examination
*p <0.01
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SBR on DAT SPECT, and 96.1 and 90.7 % by the
DAT*MIBG index, respectively.
The area under the curve was 0.864 for the H/M ratio of
MIBG myocardial scintigraphy in the delayed phase, 0.923
for DAT SPECT, and 0.981 for the combined use of these two
methods (Fig. 2). The combined use of the two methods en-
abled more accurate differentiation of DLB from AD than
either DAT SPECT or MIBG myocardial scintigraphy alone
(DAT SPECT vsMIBG, p=0.170; DAT SPECTandMIBG vs
MIBG, p<0.001; DAT SPECT and MIBG vs DAT SPECT,
p=0.012).
Patients with DLB were categorized into three differ-
ent groups by the combined use of DAT SPECT and
MIBG myocardial scintigraphy. Figure 3 shows represen-
tative DAT SPECT and MIBG myocardial scintigraphy
images of patients from the three different groups.
Forty-six patients showed reduced tracer uptake on both
DAT SPECT and MIBG myocardial scintigraphy (Fig. 3,
top). Twenty-one patients showed decreased DAT uptake
but normal MIBG uptake (Fig. 3, middle). Nine patients
showed normal DAT uptake and decreased MIBG uptake
(Fig. 3, bottom).
MIBG DAT-SPECT DAT-SPECT*MIBG
AD AD ADDLB DLB DLB
p < 0.0001 p < 0.0001 p < 0.0001
H/M SBR SBR*H/M
Fig. 1 Scatter plots of the H/M
ratio on MIBG myocardial
scintigraphy in the delayed phase
(left), SBR on DAT SPECT
(middle), and DAT*MIBG index
(right) in patients with DLB and
AD. Cutoff lines were set at 1.77
(2 SDs below the control, right),
4.18 (2 SDs below the control,
middle) and 10.18 (the best value
in ROC analysis, left)
MIBG AUC=0.864
DAT-SPECT AUC=0.923  
DAT× MIBG AUC=0.981
Fig. 2 ROC curves to differentiate DLB from AD. The combination of
DAT SPECT and MIBG myocardial scintigraphy enabled more accurate










Fig. 3 Example images of DAT SPECT and MIBG myocardial
scintigraphy of patients with DLB. Group 1: low uptakes on both DAT
SPECT and MIBG myocardial scintigraphy (top). Group 2: low uptake
on DAT SPECT and normal on MIBG myocardial scintigraphy (middle).
Group 3: normal on DAT SPECT and low uptake on MIBG myocardial
scintigraphy (bottom)
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Table 2 shows a summary of the symptoms observed in
patients with DLB in the three groups. The appearance of
parkinsonism was significantly more frequent in patients from
groups 1 and 2 that had abnormal DAT SPECT data, com-
pared with patients from group 3 that had normal DAT SPECT
data (group 1 vs group 3: p<0.001; group 2 vs group 3:
p<0.001). On the other hand, the appearance of RBD in pa-
tients of groups 1 and 3 that had abnormal MIBG uptake was
significantly more frequent compared with patients from
group 2 that had normal MIBG uptake (group 1 vs group 2:
p<0.01; group 3 vs group 2: p<0.05).
Discussion
In agreement with previous studies [7–26], we confirmed that
a reduction in both striatal DAT uptake and cardiac MIBG
uptake are characteristic features of DLB, and the combined
use of DAT SPECT and MIBG myocardial scintigraphy was
more useful for differentiating DLB from AD, compared with
either of these two methods alone. Moreover, we found the
presence of parkinsonism at a significantly higher frequency
in patients with DLB who had low DAT uptake. On the other
hand, RBD was frequently observed in patients with DLB
who showed abnormali t ies on MIBG myocardial
scintigraphy.
Previous studies in which neuropathological autopsy was
performed [10, 41] suggested that DAT imaging assists in the
diagnosis of patients with DLB. A recent meta-analysis study
reported a pooled sensitivity of 86.5 % and a specificity of
93.6 % for the differentiation of DLB from non-DLB using
DAT SPECT [26]. In our present study, the sensitivity and
specificity of differentiating DLB from AD by DAT SPECT
were 88.2 and 88.9 %, respectively, which were consistent
with the results of previous studies (sensitivities of 80 % and
specificities of 90–94 %) [7–9].
In DLB, the loss of dopaminergic cells is accompanied
by the loss of DATs (presynaptic receptors). A previous
in vitro study suggested that the loss of DAT and the loss
of striatal dopamine content are linearly correlated [42]. Our
result showing the significantly frequent appearance of par-
kinsonism in patients with DLB who showed abnormalities
on DAT SPECT was consistent with this previous in vitro
study. In patients with PD, the severity of motor symptoms
often correlates inversely with DAT density [43, 44]. How-
ever, this association may be different in patients with DLB.
Previous studies did not identify an association between the
severity of parkinsonism and striatal DAT uptake in DLB
patients [12, 45]. These results were consistent with our
results, in which no significant difference in Hoehn and Yahr
score was observed between patients with DLB who had
low DAT uptake and those who had normal DAT uptake.
There appears to be a difference in DAT uptake in the basal
ganglia between PD and DLB patients. Previous studies [12,
46] showed that patients with DLB had significantly lower
DAT uptake mainly in the caudate nucleus. On the other
hand, patients with PD had significantly lower DAT uptake,
mainly in the putamen. Thus, these results suggested that
basal ganglia pathology might differ between DLB and
PD. Furthermore, in patients with DLB, multifactorial pa-
thology may affect the nigrostriatal connection without
Table 2 DAT SPECT and MIBG myocardial scintigraphy in patients with DLB
Group 1 Group 2 Group 3
Low DAT uptake, low MIBG uptake Low DAT uptake, normal MIBG uptake Normal DAT uptake, low MIBG uptake
Total (n) 46 21 9
Age (mean ± SD) 80.2±5.4 80.3±4.2 79.6 ± 4.6
Sex (male/female) 26/20 11/10 5/4
Prob./poss.a 28 (61 %)/18 (39 %) 6 (29 %)/15 (71 %) 2 (22 %)/7 (78 %)
SBR on DAT SPECT 2.29±1.03### 2.48±0.88### 5.38±0.58
H/M of MIBG 1.25±0.20*** # 2.86±0.61### 1.47±0.21
MMSE 23.2±4.3 21.0±5.1 21.9±6.0
Hoehn and Yahr score 2.2±0.9 2.2±1.2 1.0±1.4
Parkinsonism, n (%) 38 (83 %)### 18 (86 %)### 2 (22 %)
Hallucination, n (%) 21 (46 %) 5 (24 %) 3 (33 %)
Fluctuation, n (%) 11 (24 %) 3 (14 %) 2 (22 %)
RBD, n (%) 23 (50 %)** 2 (10 %)# 4 (44 %)
MMSEMini-Mental State Examination
*p< 0.05; **p< 0.01; ***p< 0.001 (vs low DAT uptake/normal MIBG uptake)
#p < 0.05; ##p< 0.01; ###p<0.001 (vs normal DAT uptake/low MIBG uptake)
a Diagnosed as having DLB, as described in the manuscript
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affecting DAT binding. This was observed in a study by Liu
et al., in which parkinsonism was induced by the deposition
of tangles in the basal ganglia [47].
Many studies reported the coexistence of DLB and AD
pathologies. Most patients with DLB also demonstrate AD
pathology, including cortical amyloid plaques and neurofibril-
lary tangles [4, 48, 49]. On the other hand, a study by the
Alzheimer’s Disease Neuroimaging Initiative reported that
45.5 % of patients with a diagnosis of AD before death also
had DLB pathology [50]. O’Brien et al. reported that 63 % of
patients whose diagnosis had changed from possible DLB at
baseline to probable DLB at follow-up demonstrated abnor-
malities onDAT imaging [11]. In our study, three patients with
AD had abnormal DAT uptake. Particularly for our present
study, to determine whether DAT SPECT is useful for the
diagnosis of DLB, we only used the clinical signs from the
consortium on DLB international workshop criteria [4] for the
diagnosis of DLB. Based on strict diagnostic criteria, these
three patients were considered as possible DLB. Therefore,
for these three patients, careful follow-up and observation of
the appearance of characteristic clinical signs of DLB are
necessary.
In our study, the sensitivity and specificity in differentiating
DLB fromAD using the H/M ratio ofMIBG uptake were 72.4
and 94.4 %, respectively. Various studies have reported the
diagnostic accuracy of MIBG myocardial scintigraphy. Sev-
eral single-center studies [17–23] have demonstrated lower
myocardial MIBG uptake in patients with DLB than in pa-
tients with the other dementias, with high sensitivity and spec-
ificity (both were approximately 90 %). The usefulness of
MIBG myocardial scintigraphy in the diagnosis of DLB was
recently suggested by a meta-analysis study [25]. In this study,
MIBG myocardial scintigraphy demonstrated a high pooled
sensitivity (98 %) and specificity (94 %) in the differential
diagnosis of DLB and the other dementias. However, a recent
multicenter study in Japan [24] reported a sensitivity of
68.9 % and a specificity of 87.0 % in all patients, which was
consistent with our study. Moreover, this study reported that
the sensitivity and specificity in university hospitals were 91.1
and 84.8 %, respectively. The variation in these results might
be a result of selection bias. More typical DLB patients might
have been enrolled in the single-center studies. Moreover, the
fact that the mean age of patients with DLB in our study was
80.2 years, which is higher than that of the other studies, may
also be a reason, because myocardial MIBG uptake is known
to significantly decrease with age [51].
In our study, the patients with DLBwho showed abnormal-
ities on MIBG myocardial scintigraphy had a significantly
higher frequency of RBD. Miyamoto et al. reported markedly
reduced MIBG uptake in patients with idiopathic RBD, PD,
and DLB [52, 53]. On the other hand, a more profound reduc-
tion in cardiac MIBG uptake was reported in patients with
DLB compared with patients with PD [54]. One study [53]
reported that the reduction in MIBG uptake did not signifi-
cantly differ between patients with idiopathic RBD and DLB.
The results of these studies using MIBG myocardial scintig-
raphy, including our results, suggested a strong association
between RBD and DLB in Lewy body disease.
IPrevious studies [14, 15, 27–29] showed that the com-
bined use of DAT SPECT and MIBG myocardial scintigra-
phy improved the diagnostic accuracy for PS and DLB.
Camacho et al. showed that there was a positive association
between the results of DAT SPECT and those of MIBG
myocardial scintigraphy. Moreover, a close association be-
tween DAT SPECT and the presence of parkinsonism was
also found [14], which is consistent with our present study.
One study reported that both DAT SPECT and MIBG myo-
cardial scintigraphy showed high diagnostic accuracy (90 %)
to differentiate DLB from the other dementias [15].
Novellino et al. reported that the combined use of both
DAT SPECT and MIBG myocardial scintigraphy in patients
with mixed tremors and additional extrapyramidal symptoms
can help differentiate patients with essential tremor from
those with PD and parkinsonism [28]. Kim et al. reported
that the combined use of these techniques can predict the
prognosis of patients with drug-induced parkinsonism [29].
These two studies suggested that the combined use of DAT
SPECT and MIBG myocardial scintigraphy is useful for the
diagnosis of Lewy body disease, which is usually difficult.
We categorized patients with DLB into three different
groups from the results of both DAT SPECT and MIBG
myocardial scintigraphy. Approximately 40 % of the patients
displayed abnormalities on either DAT SPECT or MIBG
myocardial scintigraphy. Moreover, parkinsonism was found
at a significantly higher frequency in patients with DLB who
had low DAT uptake than in those who had normal DAT
uptake. On the other hand, RBD was frequently observed in
patients with DLB who displayed abnormalities on MIBG
myocardial scintigraphy. Patients displaying low uptake on
both DAT SPECT and MIBG myocardial scintigraphy dem-
onstrated typical clinical symptoms, suggesting an associa-
tion between abnormalities on DAT SPECT or MIBG myo-
cardial scintigraphy and clinical symptoms. Furthermore, the
combined use of DAT SPECT and MIBG myocardial scin-
tigraphy was suggested to enable the detection of patients
with abnormalities on only either of the methods. However,
we would like to note that for patients in whom either DAT
SPECT or MIBG myocardial scintigraphy cannot be per-
formed (e.g., DAT: patients with an infarction in the basal
ganglia, patients who are unable to stop the use of medica-
tions that affect DAT uptake, etc.; MIBG: patients with heart
disease or diabetes mellitus, or patients taking medications
that affect MIBG uptake, etc.), the other method can be
used. Our results showed that there was no significant dif-
ference between DAT SPECT and MIBG myocardial scin-
tigraphy (p=0.170) in diagnostic accuracy evaluated by
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ROC analysis. Moreover, when there is difficulty in diag-
nosing the patient after performing either of these methods,
it is suggested that the other method should be performed.
This study has several critical limitations. Firstly, this study
was carried out in a single memory disorder clinic; therefore, the
number of patients enrolled in each treatment group was relative-
ly small. Secondly, to determine whether DAT SPECT is useful
for the diagnosis of DLB, we used the consortium on DLB
international workshop criteria [4] as well as low DAT uptake
in the basal ganglia. However, there appeared to be no problems
in using these criteria, as all patients with DLB in this study were
probable DLB patients based on the strict DLB international
workshop criteria [4]. Thirdly, the DAT*MIBG index is an orig-
inal index that we devised for this study. Statistical weightingwas
not taken into account when setting this index. Therefore, further
studies are necessary to examine the validity of the DAT*MIBG
index. A potential limitation of the present study is the lack of
autopsy confirmation in all cases. We carefully applied rigorous
standardized sets of diagnostic criteria, all of which have been
shown to have a positive predictive value of greater than 80 %
when judged by postmortem diagnosis [55, 56]. Further large
multicenter studies, with consideration of the results of patholog-
ical examination, are required to confirm our results.
In conclusion, a combination of DAT SPECT and MIBG
myocardial scintigraphy improved the sensitivity of the detec-
tion of patients with DLB. In particular, this method may pro-
vide a powerful differential diagnostic tool when it is difficult
to differentiate patients with DLB from those with AD using
either DAT SPECT or MIBG myocardial scintigraphy alone.
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